This partnership aims to address care gaps by identifying untreated and undertreated patients at scale.

The new surgical technique incorporates a new surgical clamp that maintains eye pressure during the insertion of two tissue patches in immediate succession while minimizing damage to the surrounding tissue.

Focused on corneal disease research, Deng has been part of ARVO in various roles for more than 20 years.

ABCA4-associated retinopathies include Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.

The pivotal phase 3 clinical trial is the first of 2 that will evaluate the use of DURAVYU for the treatment of wet age-related macular degeneration.

Join global experts at the 2025 International SPECTRALIS Symposium in Heidelberg, exploring innovations in ophthalmology and space-related ocular health.

New research links diffuse-trickling patterns in fundus autofluorescence to increased ellipsoidal zone loss, highlighting potential biomarkers for rapid geographic atrophy progression.

The cross sector initiative that intends to drive a shift from reactive to proactive health care by leveraging ocular data through the means of oculomics.

The results of an investigation into iRORA identified a wide spectrum of fundus autofluorescence patterns that corresponded with iRORA lesions and that those patterns were associated with conversion to cRORA over time.

The designation is based off previously reported phase 3 data from the ongoing DRAGON trial.

The system was taught quality standards by being fed more than 1400 images from different parts of the retina taken by adaptive-optics ophthalmoscopy.

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with just one refill every 9 months.

The recent study details the diagnostic value of a multimodal model utilizing both types of biomarkers when compared to unimodal models.

DREAM is an acronym for deep imaging depth, rapid sweeping speed, extensive scan range, accurate results, and multimodal imaging capabilities.

In total, 613,690 images used for screening were included in the study.

Lineage Cell Therapeutics will be presenting data on the safety and tolerability of RG6501 (OpRegen) for the treatment of geographic atrophy, secondary to age-related macular degeneration during the upcoming Clinical Trials at the Summit 2025 meeting.

Financing will fund phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer’s Disease and diabetic macular edema (DME).

Kriya Therapeutics presented preclinical data on its gene therapy candidate for the treatment of geographic atrophy.

Ashvattha Therapeutics announced positive interim phase 2 results for migaldendranib for the treatment of AMD and DME.

SYL1801 is a treatment for neovascular macular degeneration administered via eye drops.

A recent analysis reveals a strong link between photoreceptor health and visual function in geographic atrophy, emphasizing the importance of EZ integrity.

Valeda met the primary end point in the US LIGHTSIDE III trial, improving the best corrected visual acuity in patients for 24 months of >5 letters or equivalent to 1 line improvement on the eye chart, according to the company.

A recent study reveals how geographic atrophy affects patients' vision and quality of life, highlighting their coping strategies and need for better resources.

New research reveals how low blood sugar can damage the retina in diabetes, highlighting potential treatments targeting specific proteins to prevent vision loss.